At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Olpasirandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(a)
In Brief
A Phase 1 clinical trial evaluating Olpasiran for Elevated Serum Lipoprotein(a). Completed, enrolled 24 participants across 1 site.
Detailed Summary
The main objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of Olpasiran in Chinese participants with elevated serum lipoprotein(a) (Lp\[a\]).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElevated Serum Lipoprotein(a)
CountriesHong Kong
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedAug 2021
Primary CompletionNov 2021
Study CompletionMar 2022
TodayJul 2026
First PostedAug 3, 2021
Enrollment StartJul 28, 2021
Primary CompletionNov 12, 2021
Study CompletionMar 18, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.9 years ago
Interventions
Olpasirandrug
Subcutaneous injection